

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ANTI-TUMOR NANODRUG “EPIRUBICIN HYDROCHLORIDE LIPOSOME INJECTION” WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Epirubicin Hydrochloride Liposome Injection” (the “**Product**”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Company, was granted approval by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is able to reduce the distribution of drug in normal tissues by encapsulating the active ingredient epirubicin hydrochloride in PEGylated liposome and achieve targeting to tumor area with the enhanced permeability and retention (EPR) effect. Compared to conventional injection, the Product can significantly reduce the toxic side-effects and enhance the efficacy. The planned indication of the Product is solid tumors. Based on the results of non-clinical studies, the Product has a promising prospect of demonstrating good anti-tumor efficacy in the clinical trials.

“Epirubicin Hydrochloride Liposome Injection” is a class 2 chemical drug and currently there is no product of the same type available in the global market. The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

** for identification purpose only*

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 22 October 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.